+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID07019766

National Longitudinal Study of Large Granular Lymphocytic Leukemia Patients in China Tracking Treatment, Outcomes, and Healthcare Costs

Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-06-17

9999

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a large-scale, long-term study on hematological diseases, focusing on large granular lymphocytic leukemia LGLL, a disorder affecting blood and blood-forming organs. This study aims to better understand the incidence, risk factors, treatment effectiveness, patient outcomes, and healthcare costs related to LGLL in China, addressing gaps from previous smaller or limited studies. The study combines retrospective and prospective observational methods. It collects detailed patient information from medical records, including diagnosis, treatment, and health costs. Patients diagnosed with LGLL from January 1, 2000, onward at participating hospitals are included. Questionnaires assess patient exposure, and ongoing follow-up gathers prognosis and health-related quality of life data. Participants will have their hematologic response evaluated at the start, and then at 6, 12, and 24 months after treatment, with additional assessments at study completion. Researchers will examine clinical features, treatment patterns, relapses, mortality, and long-term outcomes. The study involves continuous monitoring over many years to provide comprehensive insights into LGLL progression and management.

CONDITIONS

Brief Title

National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia

Research Team

L

Lele Zhang, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here